Telomir Pharmaceuticals, Inc. · NASDAQ:TELO
Telomir Pharmaceuticals — Investor Presentation (August 2024)
27 slides from Telomir Pharmaceuticals's investor presentation, August 2024
Slide 1: 2024 Investor Presentation
Erez Aminov Chairman and CEO August 2024 Nasdaq: TELO 2024 | INVESTOR PRESENTATION 1
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation and the statements of the Company’s management related thereto contains “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and
Slide 3: Telomir Pharmaceuticals At-A-Glance
TELOMIR PHARMACEUTICALS AT-A-GLANCE Telomir Pharmaceuticals is a preclinical stage Founded pharmaceutical company focused on the development August 2021 and commercialization of Telomir-1. Telomir-1 is the first innovative and novel small molecule targeted at lengthening the DNA’s protective telomer
Slide 4: What Is Telomir-1
WHAT IS TELOMIR-1 Telomir-1 is under investigation to potentially provide a therapeutic intervention against age-related inflammatory conditions Novel small Oral therapeutic Targeting the Elongate and Interrupt and No FDA molecule treatment to treatment of stimulate prevent IL-17 approved oral IL- p
Slide 5: Artificial Intelligence (AI) Modeling of Telomir-1
ARTIFICIAL INTELLIGENCE (AI) MODELING OF TELOMIR-1 TELOMIR collaborated with InSilicoTrials, an innovator in leveraging AI and simulations to enhance drug development, to perform advanced AI modeling on Telomir-1. Early research has confirmed the mechanism of action of Telomir-1 and suggests that it
Slide 6: Elizabeth Blackburn: Nobel Prize on Telomeres
ELIZABETH BLACKBURN: NOBEL PRIZE ON TELOMERES The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine 2009 jointly to Elizabeth Blackburn, Carol Greider and Jack Szostak for the discovery of how chromosomes are protected by telomeres and the enzyme telom
Slide 7: What Are Telomeres
WHAT ARE TELOMERES Female Male XX XY Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins (TTAGGG). During cell division, telomeres allow cells to Genetic Material divide without losing genes by protecting the chromosome ends from becoming damaged similar to a
Slide 8: Telomere Regulation
TELOMERE REGULATION The overarching goal of the study is to provide evidence that TELOMIR-1 can promote telomere elongation and stability, leading to a slower progression of diseases and self-renewal. We have limited stem cells to repair ourselves due to limits on telomeres and their shortening with
Slide 9: In Vitro Human Stem Cell Therapy with Frontage Laboratories
IN VITRO HUMAN STEM CELL THERAPY WITH FRONTAGE LABORATORIES TELOMERE LENGTH DETERMINATION (TTAGGG) Total Telomere Length Total Telomere Length 4000 Female Male 5000 XX XY Passage 8 Total Telomere Length/ Total Telomere Length/ Diploid Cell (Kb) 4000 Diploid Cell (Kb) 3000 3000 2000 2000 Genetic Mate
Slide 10: Advantages of Elongating Telomeres
ADVANTAGES OF ELONGATING TELOMERES • Stress shortens telomeres • People who regularly eat sugar laden and processed food have shorter telomeres • People who regularly do extreme physical activity have shorter telomeres • Astronauts have shorter telomeres • People who have sun burns or who smoke or v
Slide 11: Stem Cells and Telomere Elongation
STEM CELLS AND TELOMERE ELONGATION Imagine if you could repair each organ or tissue with age-related damage and make that tissue young again • Young heart • Young blood vessels • Young brain • Young joints • Young back discs • Young lung • Young kidney • Young gut • Young skin (additional applicatio
Slide 12: The Study: Harvesting and Culturing Stem Cells - Stroke
THE STUDY: HARVESTING AND CULTURING STEM CELLS - STROKE • Stem cells are the matriarchs of the human body—the cells from which all other cells are derived. Another way stem cells are maternal: they come in and repair things • But let’s say you can grow stem cells--- they did that at Stanford for 18
Slide 13: The Study: Stem Cell Repair – Heart Transplantation
THE STUDY: STEM CELL REPAIR – HEART TRANSPLANTATION • We learned this after transplantation of a male heart into a female person…that male heart initially had an ejection fraction of 55%. • The male heart subsequently had a heart attack. The woman got to the hospital and had blood flow to her male h
Slide 14: New York Times: Why Do We Age?
NEW YORK TIMES: WHY DO WE AGE? According to some estimates, consumers spend $62 billion a year on “anti-aging” treatments. Scientists are working to understand the biological causes of aging to slow or stop its visible signs and, more importantly, age- related diseases. Why Do We Age? • Problems wit
Slide 15: Key Investment Highlights
KEY INVESTMENT HIGHTLIGHTS Treatment Indications – Elongating telomeres, age-related inflammatory diseases (osteoarthritis), and hemochromatosis. Large Market Opportunity Osteoarthritis – Market Opportunity $7.4 billion worldwide in 2021, expected CAGR of 8.5% through 2030* Global longevity- Accordi
Slide 16: Commercial Opportunity: Osteoarthritis
COMMERCIAL OPPORTUNITY Telomir is developing the novel asset Telomir-1 as a treatment for age-related inflammatory diseases OSTEOARTHRITIS: Most common cause of disability Approximately 528 million people worldwide with ~344 million classified as moderate or severe* $7.4 billion worldwide in 2021, e
Slide 17: Intellectual Property
INTELLECTUAL PROPERTY Patent rights are licensed from an affiliated IP development company under a perpetual, worldwide exclusive license agreement that bears an 8% running royalty. Worldwide Patent Pending for Telomir-1 Nasdaq: TELO 17
Slide 18: World Class Vendors
WORLD CLASS VENDORS GLOBAL NEW JERSEY PENNSYLVANIA GLOBAL • IND Services • IND Services • Animal Toxicology • BioMap Platform • Phase 1 • Phase I Human Program Superior Human Disease • Phase 2 Clinical Trial Site (Dog and Rat Toxicology, Models • Phase 3 • 160 beds across 3 DMPK), Genotoxicology, •
Slide 19: Anticipated Timeline for Product Development
ANTICIPATED TIMELINE FOR PRODUCT DEVELOPMENT Pre-clinical work is underway and initial IND is expected to be filed in Q1 2025 Q1 –Q2 2023 Q4 2023 Q1 2024 Q2 2024 Q3 - Q4 2024 Computational Plasma Protein Binding Rat Osteoarthritis ^^GMP Dog 28-day Toxicology Mutagenicity with IL-17 Analysis Reaction
Slide 20: Executive Management
EXECUTIVE MANAGEMENT President Erez Aminov Michelle Yanez, MBA Itzchak Angel, PhD Chairman & CEO Chief Financial Officer Chief Scientific Advisor • In August 2024, he was appointed Chairman and • Became Chief Financial Officer in June 2024, • Over 40 years of executive leadership in the CEO of Telom
Slide 21: Advisory Board
ADVISORY BOARD MARK OKEN Michael Roizen, M.D. ALEX WEISMAN, PH.D. Senior Advisor Special Advisor on Age Reversal Scientific Advisor Mr. Oken is the chairman of Falfurrias Capital and has Dr. Alex Weisman, Ph.D. in biochemistry, is the founder Michael F. Roizen, MD, has had a distinguished career in
Slide 22: Mouse Pictures
MOUSE PICTURES 22
Slide 23: Mouse Videos
MOUSE VIDEOS 23
Slide 24: Dog Pictures
DOG PICTURES 24
Slide 25: Dog Video
DOG VIDEO 25
Slide 26: Summary
SUMMARY • Developing and commercializing Telomir-1, a potential treatment for age-related diseases • Telomir-1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal of stem cells. • Large market opportunity for the treatment of multiple indicati
Slide 27: Thank You for Your Consideration
CONTA CT: Erez Aminov Chairman and CEO erez@telomirpharma.com THANK YOU FOR YOUR CONSIDERATION Nasdaq: TELO 27
Telomir Pharmaceuticals — Investor Presentation (August 2024) on 6ix